ꢀ
ꢀ
D.E. Gonzalez-Juarez et al. / Tetrahedron 68 (2012) 7187e7195
7193
EtOAc 1:1); IR (CHCl3, cmꢁ1): 2256, 1699; dH: 6.86 (1H, m, H-4),
6.83 (1H, dd, J¼8.4, 2.5 Hz, H-6), 6.76 (1H, br d, J¼8.4 Hz, H-7),
3.80 (3H, s, OMe), 3.51 (1H, dd, J¼8.1, 5.1 Hz, H-3), 3.18 (3H, s,
NMe), 2.57 (2H, m, H-9), 2.36 and 2.15 (2H, m, H-8); dC: 175.7 (C-
2), 155.9 (C-5), 137.5 (C-7a), 128.0 (C-3a), 118.9 (CN), 112.5 (C-6),
111.2 (C-4), 108.5 (C-7), 55.6 (NMe), 43.8 (C-3), 26.4 (C-8), 26.1
(OMe), 13.8 (C-9); GCeMS (EI, 70 eV): m/z (%)¼230 (Mþ, 100), 216
(84), 177 (30); HRESI/APCIMS: m/z calcd for C13H14N2O2þHþ:
231.1133; found: 231.1129.
HRESI/APCIMS: m/z calcd for C15H20N2O3þH: 277.1547; found:
277.1551.
4.4.3. N-{3-[1-(4-Methoxybenzyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]
propyl}acetamide (4c). Application of the typical procedure using
3-propionitrile oxindole 3c (200 mg, 0.65 mmol) gave 3-
propylacetamide oxindole 4c as pale yellow oil (172 mg, 75%). Rf:
0.41 (CH2Cl2/MeOH 9:1); IR (CHCl3, cmꢁ1): 3451, 3366, 1700, 1669;
dH: 7.25e7.19 (3H, m, Ho and H-4), 7.17 (1H, tdd, J¼8.1, 1.3, 0.7 Hz, H-
6), 7.02 (1H, td, J¼7.9, 1.0 Hz, H-5), 6.83 (2H, m, Hm), 6.76 (1H, br d,
J¼7.8 Hz, H-7), 5.96 (1H, br s, NH), 4.86 and 4.79 (2H, AB, J¼15.2 Hz,
CH2), 3.76 (3H, s, OMe), 3.54 (1H, t, J¼5.4 Hz, H-3), 3.21 (2H, m, H-
10), 2.01 (2H, m, H-8),1.95 (3H, s, COMe),1.58 (2H, m, H-9); dC: 177.9
(C-2), 170.2 (COMe), 159.0 (Cp), 143.2 (C-7a), 128.6 (2C, Co), 128.6 (C-
3a), 127.9 (C-6), 127.8 (Ci), 123.8 (C-4), 122.5 (C-5), 114.1 (2C, Cm),
109.0 (C-7), 55.2 (OMe), 44.9 (C-3), 43.1 (NCH2), 39.1 (C-10), 27.7 (C-
8), 25.6 (C-9), 23.2 (COMe). GCeMS (EI, 70 eV): m/z (%)¼352 (Mþ,
7), 121 (100); HRESI/APCIMS: m/z calcd for C21H24N2O3þHþ:
353.1865; found: 353.1859.
4.3.3. 3-[1-(4-Methoxybenzyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]
propanenitrile (3c). Application of the typical procedure using
nitrile-substituted cyclopropane anti-1c (200 mg, 0.66 mmol)
gave 3-propylacetamide oxindole 3c as colorless needles (90 mg,
45%), mp 109e110 ꢀC (acetone/hexane). Rf: 0.54 (hexane/EtOAc
1:1); IR (CHCl3, cmꢁ1): 2253, 1704; dH: 7.23 (2H, m, Ho), 7.23 (1H,
partially overlapped, H-4), 7.21 (1H, partially overlapped, H-6),
7.04 (1H, td, J¼7.6, 0.9 Hz, H-5), 6.84 (2H, m, Hm), 6.79 (1H, br d,
J¼6.8 Hz, H-7), 4.83 (2H, s, NCH2), 3.76 (3H, s, OMe), 3.60 (1H, m,
H-3), 2.63 (2H, m, H-9), 2.43 and 2.21 (2H, m, H-8); dC: 176.3 (C-
2), 159.0 (Cp), 143.2 (C-7a), 128.6 (2C, Co), 128.5 (C-6), 127.6 (Ci),
126.8 (C-3a), 123.7 (C-4), 122.6 (C-5), 119.0 (CN), 114.1 (2C, Cm),
109.3 (C-7), 55.1 (OMe), 43.5 (C-3), 43.1 (NCH2), 26.6 (C-8), 13.9
(C-9); GCeMS (EI, 70 eV): m/z (%)¼306 (Mþ, 20), 121 (100);
HRESI/APCIMS: m/z calcd for C19H18N2O2: 329.1260þNa; found:
329.1261.
4.4.4. N-[3-(1-Methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)propyl]acet-
amide (4a) and N-{[(1R*,2R*)-10-methyl-20-oxo-10,20-dihydrospiro
[cyclopropane-1,30-indol]-2-yl]methyl}acetamide
(anti-
5a). Application of the typical procedure using spirooxindole anti-
1a (200 mg, 1.0 mmol) gave a pale yellow oil containing an in-
separable mixture of 4a and anti-5a in a 3:1 ratio (187 mg total,
75%). For 4a: NMR data were consistent with those described above
for the same compound prepared from 3a. For anti-5a: Rf: 0.47
(CH2Cl2/MeOH 9:1); dH: 7.31 (1H, partially overlapped, H-6), 7.06
(1H, dd, J¼7.1, 1.0 Hz, H-4), 7.05 (1H, td, J¼7.1, 1.0 Hz, H-5), 6.93 (1H,
br d, J¼7.8 Hz, H-7), 5.84 (1H, br s, NH), 3.97 (1H, m, H-10), 3.27 (3H,
s, NMe), 2.13 (1H, m, H-9), 1.90 (3H, s, COMe) 1.90 and 1.52 (2H,
partially overlapped, H-8); dC: 176.2 (C-2), 170.1 (COMe), 144.0 (C-
7a), 127.2 (C-3a), 127.1 (C-6), 122.0 (C-5), 120.7 (C-4), 108.2 (C-7),
38.1 (C-10), 31.2 (C-3), 31.2 (C-9), 22.8 (C-8), 26.6 (NMe), 23.1
(COMe); GCeMS (EI, 70 eV): m/z (%)¼244 (Mþ, 70), 159 (100).
4.4. Typical catalytic hydrogenolysis procedure in Ac2O:
catalytic hydrogenolysis of 3a
A solution of 3-propionitrile oxindole 3a (200 mg, 1.0 mmol)
was hydrogenated in a Parr bomb over W-5 Raney-Ni catalyst
(550 mg) in dry Ac2O (8 mL) at room temperature under 45 psi H2
for 5 h. The mixture was filtered through Celite and concentrated in
vacuo to dryness. The residue was dissolved in CH2Cl2 (50 mL) and
washed with water and brine. The organic layer was dried over
Na2SO4, filtered, and concentrated, and the residue was purified by
flash chromatography on silica (CH2Cl2/MeOH 99:1) to give 3-
propylacetamide oxindole 4a as pale yellow oil (172 mg, 70%).
4.4.5. N-[3-(5-Methoxy-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)
propyl]acetamide (4b) and N-{[(1R*,2R*)-50-methoxy-10-methyl-20-
oxo-10,20-dihydrospiro[cyclopropane-1,30-indol]-2-yl]methyl}acet-
amide (anti-5b). Application of the typical procedure using spi-
rooxindole anti-1b (200 g, 0.88 mmol) gave a pale yellow oil
containing an inseparable mixture of 4b and anti-5b in a 3:1 ratio
(211 mg total, 87%). For 4b: NMR data were consistent with those
described above for the same compound prepared from 3b. For
anti-5b: Rf: 0.46 (CH2Cl2/MeOH 9:1); dH: 5.93 (1H, br s, NH), 3.97
(1H, m, H-8), 3.26 (3H, s, NMe), 2.14 (1H, m, H-9), 1.93 (3H, s, COMe)
(other signals indistinguishable); dC: 176.0 (C-2), 170.2 (COMe),
155.6 (C-5), 137.6 (C-7a), 128.7 (C-3a), 111.3 (C-4), 108.4 (C-7), 55.8
(OMe), 37.8 (C-10), 31.6 (C-3), 31.1 (C-9), 26.6 (NMe), 23.0 (COMe),
22.8 (C-8); GCeMS (EI, 70 eV): m/z (%)¼274 (Mþ, 100), 216 (26), 202
(42), 174 (47).
4.4.1. N-[3-(1-Methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)propyl]acet-
amide (4a). Rf: 0.44 (CH2Cl2/MeOH 9:1); IR (CHCl3, cmꢁ1): 3453,
3350, 1697, 1669; dH: 7.28 (1H, td, J¼8.0, 1.3 Hz, H-6), 7.25 (1H, br d,
J¼7.7 Hz, H-4), 7.07 (1H, td, J¼7.5, 1.0 Hz, H-5), 6.84 (1H, br d,
J¼7.5 Hz, H-7), 6.02 (1H, br s, NH), 3.46 (1H, t, J¼6.0 Hz, H-3), 3.25
(2H, m, H-10), 3.20 (3H, s, NMe), 2.00 (2H, m, H-8), 1.95 (3H, s,
COMe),1.54 (2H, m, H-9); dC: 177.8 (C-2),170.2 (COMe),144.1 (C-7a),
128.6 (C-3a), 128.0 (C-6), 123.7 (C-4), 122.5 (C-5), 108.0 (C-7), 44.9
(C-3), 39.1 (C-10), 27.6 (C-8), 26.1 (NMe), 25.6 (C-9), 23.2 (COMe).
GCeMS (EI, 70 eV): m/z (%)¼246 (Mþ, 87), 188 (100), 161 (64);
HRESI/APCIMS: m/z calcd for C14H18N2O2þHþ: 247.1446; found:
247.1448.
4.4.2. N-[3-(5-Methoxy-1-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl)
propyl]acetamide (4b). Application of the typical procedure using
3-propionitrile oxindole 3b (200 mg, 0.87 mmol) gave 3-
propylacetamide oxindole 4b as pale yellow crystals (180 mg,
75%), mp 122e125 ꢀC. Rf: 0.43 (CH2Cl2/MeOH 9:1); IR (CHCl3,
cmꢁ1): 3450, 1692; dH: 6.87 (1H, dd, J¼2.5, 0.4 Hz, H-4), 6.81 (1H,
dd, J¼8.6, 2.5 Hz, H-6), 6.73 (1H, br d, J¼8.6 Hz, H-7), 5.92 (1H, br s,
NH), 3.78 (3H, s, OMe), 3.43 (1H, t, J¼6.0 Hz, H-3), 3.24 (2H, m, H-
10), 3.16 (3H, s, NMe), 1.99 (2H, m, H-8),1.94 (3H, s, COMe), 1.54 (2H,
m, H-9); dC: 177.4 (C-2); 170.1 (COMe); 156.0 (C-5), 137.7 (C-7a),
129.9 (C-3a), 112.0 (C-6), 111.4 (C-4), 108.2 (C-7), 55.8 (OMe), 45.3
(C-3), 39.1 (C-10), 27.6 (C-8), 26.2 (NMe), 25.6 (C-9), 23.2 (COMe);
GCeMS (EI, 70 eV): m/z (%)¼276 (Mþ, 100), 217 (83), 189 (54);
4.4.6. N-{3-[1-(4-Methoxybenzyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]
propyl}acetamide (4c) and N-{[(1R*,2R*)-10-(4-methoxybenzyl)-20-
oxo-10,20-dihydrospiro[cyclopropane-1,30-indol]-2-yl]methyl}acet-
amide (anti-5c). Application of the typical procedure using spi-
rooxindole anti-1c (200 mg, 0.66 mmol) gave a pale yellow oil
containing an inseparable mixture of 4c and anti-5c in a 3:1 ratio
(195 mg total, 85%). For 4c: NMR data were consistent with those
described above for the same compound prepared from 3c. For
anti-5c: Rf: 0.43 (CH2Cl2/MeOH 9:1); dH: 7.08 (1H, br d, J¼8.0 Hz, H-
4), 7.01 (1H, br t, J¼8.1 Hz, H-5), 6.04 (1H, br s, NH), 4.94 and 4.84
(2H, AB, J¼15.9 Hz, NCH2), 3.92 and 3.24 (2H, m, H-10), 2.18 (1H, m,
H-9) (other signals indistinguishable); dC: 176.3 (C-2),170.1 (COMe),
143.0 (C-7a), 128.0 (Ci), 127.2 (C-3a), 126.9 (C-6), 121.9 (C-5), 120.8